PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Practice Signal

Restarting Anticoagulation After Intracranial Hemorrhage in AF

This review helps pharmacists decide whether and how to restart a DOAC after intracranial hemorrhage in atrial fibrillation, weighing the ischemic benefit in PRESTIGE-AF and COCROACH against the recurrent bleeding signal, ENRICH-AF's negative result, and where the bleed was.

Bottom Line

In atrial fibrillation after intracerebral hemorrhage, every randomized trial points the same way: a DOAC prevents ischemic strokes and causes more brain bleeds. PRESTIGE-AF cut ischemic stroke from 8.60 to 0.83 per 100 patient-years but raised recurrent ICH from 0.82 to 5.00, and ENRICH-AF (ESC 2026) found no reduction in stroke or embolism with edoxaban in unselected patients. Restarting is a shared decision driven by the bleed's phenotype: most defensible after deep, hypertension-related ICH with blood pressure controlled, and hardest to justify after lobar ICH or suspected cerebral amyloid angiopathy.

HR 0.05
PRESTIGE-AF: ischemic stroke with a DOAC vs no anticoagulation (95% CI 0.01-0.36); 0.83 vs 8.60 per 100 patient-years
HR 10.89
PRESTIGE-AF: recurrent ICH with a DOAC (90% CI 1.95-60.72); 5.00 vs 0.82 per 100 patient-years, noninferiority not met
HR 2.23
ENRICH-AF (ESC 2026): major bleeding with edoxaban (95% CI 1.39-3.59), with no reduction in stroke or embolism (HR 0.88)
RR 0.20 vs 3.14
Six-RCT meta-analysis, 798 patients: ischemic stroke fell, recurrent ICH tripled, all-cause death unchanged (RR 1.06)

State of Play

Patients with atrial fibrillation who survive an intracerebral hemorrhage carry two competing risks: an ischemic stroke from the AF and another bleed in the brain. For years the restart decision rested on observational cohorts, which linked restarting anticoagulation to fewer ischemic events, but those patients were restarted because clinicians judged them safe. The first randomized data came in small pieces. SoSTART (UK, 203 patients) could not show that starting anticoagulation was noninferior for recurrent intracranial hemorrhage (8% vs 4%; adjusted HR 2.42, 95% CI 0.72-8.09), and 7 of the 8 recurrent bleeds in the start group were fatal. APACHE-AF (Netherlands, 101 patients after anticoagulant-associated ICH) found no difference in stroke or vascular death with apixaban (HR 1.05, 95% CI 0.48-2.31), with 4 recurrent ICHs on apixaban vs 1 without and the same number of ischemic strokes (6 in each arm).

COCROACH, a prospectively planned individual-patient meta-analysis of four trials (412 patients), sharpened the picture. Anticoagulation cut ischemic major cardiovascular events from 19% to 4% (HR 0.27, 95% CI 0.13-0.56), but its primary outcome of any stroke or cardiovascular death was not significantly reduced (14% vs 22%; HR 0.68, 95% CI 0.42-1.10), hemorrhagic events trended higher (7% vs 5%; HR 1.80, 95% CI 0.77-4.21), and death or dependence at one year did not differ. By 2023 the shape was clear: the ischemic benefit is real, the hemorrhagic cost is real, and the trials were too small to say which wins.

The 2022 AHA/ASA guideline for spontaneous ICH, written before the larger trials, leaves restarting anticoagulation to individualized judgment. It does stress investigating the cause of every ICH, because the cause changes prevention: in the pooled data it cites, recurrence ran about 7.4% per year after cerebral amyloid angiopathy-related ICH vs 1.1% per year after other ICH.

🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this Practice Signal, every other Signal, and every deep analysis we publish, plus PDF reports.

Subscribe for $8/month →
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.
anticoagulation|atrial fibrillation|intracerebral hemorrhage|DOAC|stroke prevention|cerebral amyloid angiopathy|neurology
🎓
Synthesized and reviewed by a licensed pharmacist
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.
Thanks for the feedback!

← Back to Evidence Rounds